Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
35.35
-0.05 (-0.14%)
Jul 17, 2026, 4:00 PM EDT - Market closed
Celldex Therapeutics Stock Forecast
Stock Price Forecast
According to 16 analysts polled by S&P Global, Celldex Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $57.53. The average 1-year stock price forecast is 62.74% higher than the current stock price, while the lowest is $38 (+7.50%) and the highest is $90 (+154.60%).
Price Target: $57.53 (+62.74%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Celldex Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 13 | 12 | 12 | 13 |
| Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 15 | 15 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Reiterates $54 | Buy | Reiterates | $54 | +52.76% | Jun 30, 2026 |
| UBS | UBS | Buy Maintains $45 | Buy | Maintains | $45 | +27.30% | Jun 16, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $67 | Buy | Maintains | $67 | +89.53% | Jun 15, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $67 | Buy | Maintains | $67 | +89.53% | Jun 15, 2026 |
| Wolfe Research | Wolfe Research | Buy Maintains $51 → $44 | Buy | Maintains | $51 → $44 | +24.47% | Jun 15, 2026 |
Financial Forecast
Revenue This Year
2.63M
from 1.55M
Increased by 70.53%
Revenue Next Year
11.96M
from 2.63M
Increased by 354.03%
EPS This Year
-4.39
from -3.90
EPS Next Year
-4.50
from -4.39
EPS and Forward PE are based on non-GAAP adjusted numbers.